Surat: Anupam Rasayan India Limited (BSE: 543275, NSE: ANURAS), one of India’s leading custom synthesis and specialty chemical companies, has paid the consideration towards the transaction of a 48.2% controlling stake in Bliss GVS Pharma Limited at Rs 299 per share, marking its third strategic inorganic transaction and expanding its presence into finished dosage formulations.
The acquisition, undertaken through Mates Visa Consultancy, a wholly owned subsidiary of Anupam Rasayan, follows the definitive agreement signed on May 23, 2026, and the subsequent completion of the mandatory open offer process. With the acquisition now completed, Bliss GVS Pharma becomes an integral part of Anupam Rasayan’s expanding portfolio of businesses across specialty chemicals and pharmaceuticals.
